Calgary, Alberta, Canada, August 11, 2025 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announces the award of 142,987 deferred share units (“DSUs”) to two of Marvel’s directors, in lieu of cash payment for directors’ fees.| Marvel Biosciences
The post Marvel Announces the Second of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide Following Cessation of Drug Treatment appeared first on Marvel Biosciences.| Marvel Biosciences
The post Marvel Biosciences to Give Oral Presentation at the Annual IRSF Rett Syndrome Scientific Meeting appeared first on Marvel Biosciences.| Marvel Biosciences
New findings about Rett syndrome could open the door to better treatments for the devastating, life-shortening developmental disorder.| UVA Health Newsroom
Columnist Jacquelyn Babiarz senses that her daughter's angel wings helped a supporter fly across the finish line in record time.| Rett Syndrome News